DARCIS, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
Language :
English
Title :
Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?
Odone A, Amadasi S, White RG et al. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PLoS One 2014; 9 (11): e112017.
Sezgin E, Van Natta ML, Thorne JE et al. Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy. HIV Med 2018; 19(6): 411–419.
Salter ML, Lau B, Go VF et al. HIV infection, immune suppression and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis 2011; 53: 1256–1264.
Antela A, Aguiar C, Compston J et al. The role of tenofovir alafenamide in future HIV management. HIV Medicine 2016; 17 (Suppl. 2): 4–16.
Darcis G, Moutschen M. The effect of treatment simplification on HIV reservoirs. Lancet 2017; 4: e328–e329.
Revuelta-Herrero JL, Chamorro-de-Vega E, Rodriguez-González CG et al. Effectiveness, safety, and costs of a treatment switch to dulutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother 2018; 52 (1): 11–18.
Wijting I, Rokx C, Boucher C et al. Dolutegravir as maintenance monotherapy for hIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV 2017; 4 (12): e547–e554.
Antinori A, Arribas J, Fehr J et al. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19525.
Baril JG, Angel JB, Gill MJ et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naïve or ARV-experienced, virologically suppressed patients. PLoS One 2016; 11 (2): e0148231.
Lohse N, Obel N. Update of survival for persons with HIV infection in Denmark. Ann Intern Med 2016; 165 (10): 749–750.
Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50 (10): 1387–1396.
Weber R, Ruppik M, Rickenbach M et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013; 14: 195–207.
British HIV Association. British HIV Association guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2015 (2016 interim update). Available at: http://www.bhiva.org/HIV-1-treatment-guidelines.aspx (accessed 29 January 2019).
Günthard HF, Saag MS, Benson CA et al. Antiretroviral drugs for treatment and prevention of HIV infection. 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316(2): 192–210.
Perez-Molina JA, Rubio R, Rivero A et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15: 775–784.
Di GiambenedettoS, Fabbiani M, Quiros Roldan E et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother 2017; 72(4): 1163–1171.
Arribas JR, Girard PM, Landman R et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15(7): 785–792.
Pulido F, Ribera E, Lagarde M et al. Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial. Clin Infect Dis 2017; 65(12): 2112–2118.
Cahn P, Andrade-Villanueva J, Arribas JR et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014; 14(7): 572–580.
Perez-Molina JA, Pulido F, Di Giambenedetto S et al. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717. J Antimicrob Chemother 2018; 73(11): 2927–2935.
Cahn P, Rolón MJ, Figueroa MI et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc 2017; 20 (1): 21678.
Taiwo BO, Zheng L, Stefanescu A et al. ACTG A5353: a Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis 2018; 66: 1689–1697.
Cahn P, Sierra Madero J, Arribas JR et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393(10167): 143–155.
Libre JM, Hung CC, Brinson C et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomized, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391 (10123): 839–849.
Aboud M. 22nd International AIDS Conference. Amsterdam, The Netherlands; July 23–27, 2018. Abstract THPEB047.
Raffi F, Babiker AG, Richert L et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384 (9958): 1942–1951.
Raffi F, Babiker AG, Richert L et al. First-line RAL + DRV/r is non-inferior to TDF/FTC + DRV/r: the NEAT001/ARNR143 randomised trial. Abstract 84LB presented at CROI March 3-6 2014, Boston, MA, USA.
Llibre JM, Hung C-C, Brinson C et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomized, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391 (10123): 839–849.
Pierone G, Henegar C, Fusco J et al. Virologic response to 2-drug ART regimens among treatment-experienced HIV+ patients. CROI 2018, Abstr. 510.
Teira R, de la Fuente B, Muñoz P et al. Real world persistency with standard of care triple therapy (TT) is significantly better than dual therapies (DT) for treatment of HIV in a large Spanish cohort – VACH. Poster presented at 16th EACS. Milan, October 25-27, 2017. PE9/33.
Calvez V, Charpentier C, Wirden M et al. Antiretroviral resistance selected at failure in HIV infected patients treated by triple and dual therapies. NEAT 001. 21st CROI, Boston March 3-6 2014 84 LB. Lancet 2014; 384: 1942–1951.
Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29 (5): 484–494.
Gopalan N, Chandrasekaran P, Swamiathan S et al. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016; 13: 34.
Gopalan N, Chandrasekaran P, Swaminathan S et al. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016; 13: 34.
Ryom L, Bosesecke C, Bracchi M et al. Highlights of the 2017 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons version 9.0. HIV Medicine 2018; 19(5): 309–315.
Yukl SA, Gianella S, Sinclair E et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202 (10): 1553–1561.
Lorenzo-Redondo R, Fryer HR, Bedford T et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016; 530 (7588): 51–56.
Rosenbloom DIS, Hill AL, Laskey SB, Siliciano RF. Re-evaluating evolution in the HIV reservoir. Nature 2017; 551: E6–E8.
Gandhi M, Gandhi RT, Stefanescu A et al. Cumulative antiretroviral exposure measured in hair is not associated with measures of HIV persistence or inflammation among individuals on suppressive ART. J Infect Dis 2018; 218(2): 234–238.
Fletcher CV, Thorkelson A, Winchester L et al. Comparative lymphoid tissue pharmacokinetics (PK) of integrase inhibitors (INSTI). Presented at CROI March 4-7 2018, Boston, MA, USA.
Estes JD, Kityo C, Ssali F et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat Med 2017; 23 (11): 1271–1276.
Fletcher CV, Thorkelson A, Winchester L et al. Comparative lymphoid tissue pharmacokinetics (pk) of integrase inhibitors (INSTI). CROI 2018. Abstract 27.
Huang Y, Hoque MT, Jenabian MA et al. Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site. J Antimicrob Chemother 2016; 71 (7): 1954–1965.
Jenabian MA, Costiniuk CT, Mehraj V et al. Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults. AIDS 2016; 30 (18): 2777–2786.
Latini A, Fabbiani M, Borghi V et al. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis 2016; 16: 401.
Lundgren JD, Babiker A, El-Sadr W et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197: 1145–1155.
Tenorio AR, Zheng Y, Bosch RJ et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis, 2014; 210(8): 1248–1259.
Serrano-Villar S, Sainz T, Lee SA et al. HIV-infected individuals with low CD4/CD8 Ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 15 (10): e1004078.
Younas M, Psomas C, Reynes J et al. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy. HIV Med 2016; 17 (2): 89–105.
Reus S, Portilla J, Sánchez-Payá J et al. Low-level HIV viremia is associated with microbial translocation and inflammation. J Aquir Immune Defic Syndr 2013; 62 (2): 129–134.
Pion M, Jaramillo-Ruiz D, Martínez A et al. HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS 2013; 27 (13): 2019–2029.
Mujawar Z, Rose H, Morrow MP et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4 (11): e365.
Shrivastav S, Kino T, Cunningham T et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol 2008; 22 (2): 234–247.
Feeney ER, McAuley N, O'Halloran JA et al. The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. J Infect Dis 2013; 207 (4): 628–637.
Hatano H, Jain V, Hunt PW et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208 (1): 50–56.
Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E et al. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis 2013; 207 (8): 1221–1225.
Falasca F, Di Carlo D, De Vito C et al. Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. BMC Infect Dis 2017; 17 (1): 581.
Bastard JP, Soulié C, Fellahi S et al. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 2012; 17 (5): 915–919.
Allavena C, Rodallec A, Sécher S et al. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen. J Med Virol 2013; 85 (11): 1878–1882.
Guihot A, Dentone C, Assoumou L et al. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. AIDS 2016; 30 (2): 327–330.
Gandhi RT, McMahon DK, Bosch RJ et al. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog 2017; 13 (4): e1006285.
Chun TW, Murray D, Justement JS et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 201 (1): 135–138.
Belmonti S, Lombardi F, Quiros-Roldan E et al. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chem 2018; 73 (7): 1949–1954.
Hatano H, Yukl SA, Ferre AL et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9 (10): e1003691.
Chereau F, Madec Y, Sabin C et al. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS One 2017; 12(4): e0173893.
Castillo-Mancilla JR, Brown TT, Erlandson KM et al. Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. Clin Infect Dis 2016; 63 (12): 1661–1667.
Castillo-Mancilla JR, Morrow M, Boum Y et al. Brief report: higher ART adherence is associated with lower systemic inflammation in treatment-naive Ugandans who achieve virologic suppression. J Aquir Immune Defic Syndr 2018; 77 (5): 507–513.
Gandhi M, Gandhi RT, Stefanescu A et al. Cumulative antiretroviral exposure measured in hair is not associated with measures of HIV persistence or inflammation among individuals on suppressive ART. J Infect Dis 2018; 218 (2): 234–238.
Buzon MJ, Massanella M, Libre JM et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16 (4): 460–465.
Yukl SA, Shergill AK, McQuaid K et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24 (16): 2451–2460.
Gandhi RT, Zheng L, Bosch RJ et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7 (8): e1000321.
Rasmussen TA, McMahon JH, Chang JJ et al. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. Lancet HIV 2018; 5 (5): e221–e230.
Hatano H, Strain MC, Scherzer R et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208 (9): 1436–1442.
Petrara MR, Cattelan AM, Sasset L et al. Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus. PLoS One 2017; 12 (9): e0185128.
BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A et al. Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy. Medicine (Baltimore) 2015; 94 (17): e781.
Torres B, Guardo AC, Leal L et al. Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. J Int AIDS Soc 2014; 17: 19246.
Torres B, Guardo AC, Leal L et al. Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. J Int AIDS Soc 2014; 17: 19246.
Mussini C, Lorenzini P, Cozzi-Lepri A et al. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med 2018; 16: 79.
